Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease

NCT04669028 is registered in ClinicalTrials.gov with BioVie Inc. as lead sponsor.

NCT NCT04669028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Study of NE3107 in Subjects Who Have Mild to Moderate Probable Alzheimer's Disease
Lead sponsor
BioVie Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 5, 2021
Completion date
October 25, 2023
Enrollment
439 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease